Millipore Sigma Vibrant Logo

OP95 Anti-BRCA2 (Ab-1) Mouse mAb (2B)

Anti-BRCA2 (Ab-1), mouse monoclonal, clone 2B, recognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. It is validated for Western blotting and immunoprecipitation.

Anti-BRCA2 (Ab-1) Mouse mAb (2B) : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: Anti-Breast Cancer Susceptibility Protein

View Products on Sigmaaldrich.com
OP95
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

Species ReactivityHostAntibody Type
HMMonoclonal Antibody

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
OP95-100UG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Flacon en verre 100 μg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewRecognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
      Catalogue NumberOP95
      Brand Family Calbiochem®
      SynonymsAnti-Breast Cancer Susceptibility Protein
      References
      ReferencesAndres, J.L., et al. 1998. Oncogene 16, 2229.
      Chen, J., et al. 1998. Mol. Cell 2, 317.
      Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
      Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 13869.
      Connor, F., et al. 1997. Nat. Genet. 17, 423.
      Sharan, S.K., et al. 1997. Nature 386, 804.
      Ludwig, T., et al. 1997. Genes Dev. 11, 1226.
      Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
      Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
      Suzuki, A., et al. 1997. Genes Dev. 11, 1242.
      Wong, A.K.C., et al. 1997. J. Biol. Chem. 272, 31941.
      Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol. 23, 1.
      Goggins, M., et al. 1996. Cancer Res. 56, 5360.
      Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
      Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
      Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
      Spillman, M.A. and A.M. Bowcock. 1996. Oncogene 13, 1639.
      Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
      Wooster, R., et al. 1995. Nature 378, 789.
      Product Information
      DeclarationSold under license of U.S. Patents 5,837,492 and 6,124,104.
      FormLiquid
      FormulationIn PBS.
      Positive controlMCF7 cells
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Key Applications Immunoblotting (Western Blotting)
      Immunoprecipitation
      Application NotesImmunoblotting (2 µg/ml)
      Immunoprecipitation (2 µg)
      Application CommentsThe CAPAN-1 cell line, which has 6174delT mutation in the single BRCA2 allele, expresses a truncated BRCA2 protein of 230 kDa that contains the Anti-BRCA2 epitope and retains RAD51 binding but has lost p53 binding. Full length BRCA2 protein will co-migrate on SDS-PAGE with the catalytic subunit of DNA PK which can be detected using Anti-DNA PK, Cat. No. PC127. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena recombinant protein consisting of amino acids 1651-1821 of human BRCA2 fused to GST
      ImmunogenHuman
      Clone2B
      HostMouse
      IsotypeIgG2b
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage -20°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      OP95-100UG 04055977209709

      Documentation

      Anti-BRCA2 (Ab-1) Mouse mAb (2B) FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Anti-BRCA2 (Ab-1) Mouse mAb (2B) Certificats d'analyse

      TitreNuméro de lot
      OP95

      Références bibliographiques

      Aperçu de la référence bibliographique
      Andres, J.L., et al. 1998. Oncogene 16, 2229.
      Chen, J., et al. 1998. Mol. Cell 2, 317.
      Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
      Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 13869.
      Connor, F., et al. 1997. Nat. Genet. 17, 423.
      Sharan, S.K., et al. 1997. Nature 386, 804.
      Ludwig, T., et al. 1997. Genes Dev. 11, 1226.
      Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
      Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
      Suzuki, A., et al. 1997. Genes Dev. 11, 1242.
      Wong, A.K.C., et al. 1997. J. Biol. Chem. 272, 31941.
      Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol. 23, 1.
      Goggins, M., et al. 1996. Cancer Res. 56, 5360.
      Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
      Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
      Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
      Spillman, M.A. and A.M. Bowcock. 1996. Oncogene 13, 1639.
      Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
      Wooster, R., et al. 1995. Nature 378, 789.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision12-November-2008 JSW
      SynonymsAnti-Breast Cancer Susceptibility Protein
      ApplicationImmunoblotting (2 µg/ml)
      Immunoprecipitation (2 µg)
      DescriptionPurified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with myeloma cells. Recognizes the ~460 kDa BRCA2 protein.
      BackgroundInherited mutations in the BRCA2 gene enhances the risk of familial breast cancer with the neoplasia related to loss of the wild type allele. Human BRCA2 encodes a 3418 amino acid protein with little homology to any known proteins. Transcription of BRCA2 appears to be co-ordinately regulated with BRCA1 during proliferation and differentiation with low level expression in early G1 and maximal expression occurring during the G1/S transition of the cell cycle. While loss of BRCA2 is associated with early onset breast cancer, the gene is also critical for embryogenesis. Although some mice nullizygous for BRCA2 die during embryogenesis, there have been BRCA2 knock-out mice that do survive to adulthood, albeit with various defects particularly in DNA repair capability. Loss of BRCA2 expression in embryogenesis does not appear to affect apoptosis, per se, but proliferation is impaired, perhaps due to enhanced expression of p21WAF1. Although the precise role for BRCA2 is still to be determined, recent studies implicate BRCA2 in DNA repair and recombination processes due to association with p53 and Rad51 and co-localization with BRCA1. BRCA2 levels, as well as BRCA1 levels, decline following DNA damage and the decrease in BRCA2 accompanies activation of p53. Interestingly, BRCA2 appears capable of specifically inhibiting p53 transcriptional activity, which implicates BRCA2 as a mediator of cell cycle control and DNA repair.
      HostMouse
      Immunogen speciesHuman
      Immunogena recombinant protein consisting of amino acids 1651-1821 of human BRCA2 fused to GST
      Clone2B
      IsotypeIgG2b
      Specieshuman
      Positive controlMCF7 cells
      FormLiquid
      FormulationIn PBS.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsThe CAPAN-1 cell line, which has 6174delT mutation in the single BRCA2 allele, expresses a truncated BRCA2 protein of 230 kDa that contains the Anti-BRCA2 epitope and retains RAD51 binding but has lost p53 binding. Full length BRCA2 protein will co-migrate on SDS-PAGE with the catalytic subunit of DNA PK which can be detected using Anti-DNA PK, Cat. No. PC127. Antibody should be titrated for optimal results in individual systems.
      Storage -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Toxicity Standard Handling
      ReferencesAndres, J.L., et al. 1998. Oncogene 16, 2229.
      Chen, J., et al. 1998. Mol. Cell 2, 317.
      Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
      Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 13869.
      Connor, F., et al. 1997. Nat. Genet. 17, 423.
      Sharan, S.K., et al. 1997. Nature 386, 804.
      Ludwig, T., et al. 1997. Genes Dev. 11, 1226.
      Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
      Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
      Suzuki, A., et al. 1997. Genes Dev. 11, 1242.
      Wong, A.K.C., et al. 1997. J. Biol. Chem. 272, 31941.
      Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol. 23, 1.
      Goggins, M., et al. 1996. Cancer Res. 56, 5360.
      Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
      Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
      Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
      Spillman, M.A. and A.M. Bowcock. 1996. Oncogene 13, 1639.
      Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
      Wooster, R., et al. 1995. Nature 378, 789.